Citations (34)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Laura Mumoli, Caterina Palleria, Sara Gasparini, Rita Citraro, Angelo Labate, Edoardo Ferlazzo, Antonio Gambardella, Giovambattista De Sarro & Emilio Russo. (2015) Brivaracetam: review of its pharmacology and potential use as adjunctive therapy in patients with partial onset seizures. Drug Design, Development and Therapy 9, pages 5719-5725.
Read now
Read now
Sujeeve Sanmugabatham, Tarun Bastiampillai, Rohan Dhillon & Montaha Khan. (2009) Levetiracetam-induced psychosis. Australian and New Zealand Journal of Psychiatry 43:10, pages 977-979.
Read now
Read now
Articles from other publishers (32)
John Agbo, Zainab G. Ibrahim, Shehu Y. Magaji, Yahkub Babatunde Mutalub, Philemon Paul Mshelia & Daniel H. Mhyha. (2023) Therapeutic efficacy of voltage-gated sodium channel inhibitors in epilepsy. Acta Epileptologica 5:1.
Crossref
Crossref
Valerija Lamouret, Christoph Kurth, Tassanai Intravooth & Bernhard J. Steinhoff. (2020) Is the anticonvulsant activity of levetiracetam dose-dependent?. Seizure 83, pages 197-202.
Crossref
Crossref
Gashirai K Mbizvo, Bharath Chandrasekar, Sarah J Nevitt, Pete Dixon, Jane L Hutton & Anthony G Marson. (2020) Levetiracetam add-on for drug-resistant focal epilepsy. Cochrane Database of Systematic Reviews 2020:6.
Crossref
Crossref
Angelo Labate, Maria Eugenia Caligiuri, Francesco Fortunato, Edoardo Ferlazzo, Umberto Aguglia & Antonio Gambardella. (2020) Late drug‐resistance in mild MTLE: Can it be influenced by preexisting white matter alterations?. Epilepsia 61:5, pages 924-934.
Crossref
Crossref
Jeyakumar M, Kavitha A & Jeyanthi Arulneyam. (2019) Effect of Levetiracetam Monotherapy on Serum Cortisol Levels - A Descriptive Study. Journal of Evolution of Medical and Dental Sciences 8:49, pages 3649-3652.
Crossref
Crossref
Sudhir Chandra Sarangi, Nivendeep Kaur & Manjari Tripathi. (2019) Assessment of psychiatric and behavioral adverse effects of antiepileptic drugs monotherapy: Could they have a neuroendocrine correlation in persons with epilepsy?. Epilepsy & Behavior 100, pages 106439.
Crossref
Crossref
Kevin S. O’Connell, Nathaniel W. McGregor, Anil Malhotra, Todd Lencz, Robin Emsley & Louise Warnich. (2018) Variation within voltage-gated calcium channel genes and antipsychotic treatment response in a South African first episode schizophrenia cohort. The Pharmacogenomics Journal 19:1, pages 109-114.
Crossref
Crossref
Raghavendra Kumar Gunda, Prasada Rao Manchineni, Chaikam Gopi Reddy, Kurapati Divya, Duddu Alekhya & Ekula Jyoshna. (2019) Formulation development and in vitro evaluation of oral disintegrating tablets for newer anticonvulsant agent. Journal of Analytical & Pharmaceutical Research 8:2, pages 85-89.
Crossref
Crossref
Tony Wu, Siew-Na Lim, Jing-Jane Tsai, Yao-Chung Chuang, Chin-Wei Huang, Chun-Chieh Lin, Chang-Hung Hsu, Hong-Chung Fung & Chih-Hong Lee. (2018) A randomized, double-blind, double-dummy, multicenter trial comparing the efficacy and safety of extended- and immediate-release levetiracetam in people with partial epilepsy. Seizure 62, pages 84-90.
Crossref
Crossref
Guray Koc, Selda Keskin Guler, Omer Karadas, Tahir Yoldas & Zeki Gokcil. (2018) Fetal safety of levetiracetam use during pregnancy. Acta Neurologica Belgica 118:3, pages 503-508.
Crossref
Crossref
M. Trimboli, E. Russo, L. Mumoli, G. Tripepi, F. Fortunato, G. Mastroianni, F. Abate, G. De Sarro, A. Gambardella & A. Labate. (2018) Brand-to-generic levetiracetam switching: a 4-year prospective observational real-life study. European Journal of Neurology 25:4, pages 666-671.
Crossref
Crossref
Raluca Luchian, Emil Vinţeler, Cosmina Chiş, Mihai Vasilescu, Nicolae Leopold, João P. Prates Ramalho & Vasile Chiş. (2017) Conformational Preference and Spectroscopical Characteristics of the Active Pharmaceutical Ingredient Levetiracetam. Journal of Pharmaceutical Sciences 106:12, pages 3564-3573.
Crossref
Crossref
Li-na Zhu, Deng Chen, Da Xu, Ge Tan, Hai-Jiao Wang & Ling Liu. (2017) Newer antiepileptic drugs compared to levetiracetam as adjunctive treatments for uncontrolled focal epilepsy: An indirect comparison. Seizure 51, pages 121-132.
Crossref
Crossref
Bram Harmsen, Koen Robeyns, Johan Wouters & Tom Leyssens. (2017) A Study of Fasoracetam’s Solid State Forms: A Potential Anti-Alzheimer Pharmaceutical. Journal of Pharmaceutical Sciences 106:5, pages 1317-1321.
Crossref
Crossref
Zahra Tolou-Ghamari. (2016) Levetiracetam (Keppra): Evidence-Based Polypharmacy in Two Patients With Epilepsy. Jundishapur Journal of Chronic Disease Care 5:2.
Crossref
Crossref
Ayşe Kaçar Bayram, Mehmet Canpolat, Salih Levent Çınar, Fulya Tahan, Hakan Gumus, Sefer Kumandaş & Hüseyin Per. (2016) Drug Reaction with Eosinophilia and Systemic Symptoms Syndrome Induced by Levetiracetam in a Pediatric Patient. The Journal of Emergency Medicine 50:2, pages e61-e66.
Crossref
Crossref
Feten Béji, Sonia Taktouk, Jihène Ben Kraïem, Salem S. Al-Deyab & Hassen Amri. (2015) Two-Step Synthesis of Multifunctional γ-Lactams from γ-Lactone. Journal of Heterocyclic Chemistry 52:5, pages 1576-1579.
Crossref
Crossref
Huda A.M. Omer & Muna A.M. Kutb. (2015) Chronic histopathological effects of levetiracetam on some internal organs of adult albino rats. Egyptian Journal of Forensic Sciences 5:2, pages 41-45.
Crossref
Crossref
Jagriti Narang, Nidhi Chauhan, Nitesh Malhotra & C.S. Pundir. (2015) Nanocrystals of Zeolite Act as Enhanced Sensing Interface for Biosensing of Leviteracetum. Journal of Pharmaceutical Sciences 104:3, pages 1153-1159.
Crossref
Crossref
Joanna Lee, Veronique Daniels, Zara A. Sands, Florence Lebon, Jiye Shi & Philip C. Biggin. (2015) Exploring the Interaction of SV2A with Racetams Using Homology Modelling, Molecular Dynamics and Site-Directed Mutagenesis. PLOS ONE 10:2, pages e0116589.
Crossref
Crossref
Shahnaz Akhtar Chaudhry, Geert’t Jong & Gideon Koren. (2014) The fetal safety of Levetiracetam: A systematic review. Reproductive Toxicology 46, pages 40-45.
Crossref
Crossref
Sheila A Lewis. (2014) Newer drug treatments for focal-onset epilepsy. British Journal of Neuroscience Nursing 10:1, pages 6-12.
Crossref
Crossref
S. Renuga & S. Muthu. (2014) Molecular structure, normal coordinate analysis, harmonic vibrational frequencies, NBO, HOMO–LUMO analysis and detonation properties of (S)-2-(2-oxopyrrolidin-1-yl) butanamide by density functional methods. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy 118, pages 702-715.
Crossref
Crossref
Adriana Monserrath Orellana-Paucar, Tatiana Afrikanova, Joice Thomas, Yelaman K. Aibuldinov, Wim Dehaen, Peter A. M. de Witte & Camila V. Esguerra. (2013) Insights from Zebrafish and Mouse Models on the Activity and Safety of Ar-Turmerone as a Potential Drug Candidate for the Treatment of Epilepsy. PLoS ONE 8:12, pages e81634.
Crossref
Crossref
Emilio Russo, Eugenio Donato di Paola, Pietro Gareri, Antonio Siniscalchi, Angelo Labate, Luca Gallelli, Rita Citraro & Giovambattista De Sarro. (2013) Pharmacodynamic potentiation of antiepileptic drugs’ effects by some HMG-CoA reductase inhibitors against audiogenic seizures in DBA/2 mice. Pharmacological Research 70:1, pages 1-12.
Crossref
Crossref
Jounhong Ryan Cho, Dae Lim Koo, Eun Yeon Joo, So Mi Yoon, Eunji Ju, James Lee, Dae Young Kim & Seung Bong Hong. (2012) Effect of levetiracetam monotherapy on background EEG activity and cognition in drug-naïve epilepsy patients. Clinical Neurophysiology 123:5, pages 883-891.
Crossref
Crossref
Andrew I. Geller, Wilawan Nopkhun, Marly N. Dows-Martinez & Dale C. Strasser. (2012) Polypharmacy and the Role of Physical Medicine and Rehabilitation. PM&R 4:3, pages 198-219.
Crossref
Crossref
Jose de Leon. 2012. A Practitioner's Guide to Prescribing Antiepileptics and Mood Stabilizers for Adults with Intellectual Disabilities. A Practitioner's Guide to Prescribing Antiepileptics and Mood Stabilizers for Adults with Intellectual Disabilities
185
205
.
Antonella Gagliano, Irene Aricò, Tiziana Calarese, Rosaria Condurso, Eva Germanò, Clemente Cedro, Edoardo Spina & Rosalia Silvestri. (2011) Restless Leg Syndrome in ADHD children: Levetiracetam as a reasonable therapeutic option. Brain and Development 33:6, pages 480-486.
Crossref
Crossref
Alessandro S. De NadaiEric A. StorchJoseph F. McguireAdam B. LewinTanya K. Murphy. (2011) Evidence-Based Pharmacotherapy for Pediatric Obsessive-Compulsive Disorder and Chronic Tic Disorders. Journal of Central Nervous System Disease 3, pages JCNSD.S6616.
Crossref
Crossref
Emilio Russo, Rita Citraro, Francesca Scicchitano, Salvatore De Fazio, Eugenio D. Di Paola, Andrew Constanti & Giovambattista De Sarro. (2009) Comparison of the antiepileptogenic effects of an early long-term treatment with ethosuximide or levetiracetam in a genetic animal model of absence epilepsy. Epilepsia 51:8, pages 1560-1569.
Crossref
Crossref
Joseph P. Vande Griend, Sunny A. Linnebur & Jacquelyn L. Bainbridge. (2009) Probable levetiracetam-associated depression in the elderly: Two case reports. The American Journal of Geriatric Pharmacotherapy 7:5, pages 281-284.
Crossref
Crossref